Intradermal Recombinant Humanized Collagen Type III for Melasma: Split‐Face Randomized Comparison With Tranexamic Acid
Dermatologic Therapy · 2026-01 · 2026 (1)
DOI: 10.1155/dth/2727867 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 27.07.2026. Verfasst von Wenjie Li und 4 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Given limitations for current treatments of melasma, new safe and effective methods are being explored.
Objective
This study aimed to compare the efficacy and safety of intradermal recombinant humanized type III collagen (rhCol III) with intradermal tranexamic acid (TXA) for the treatment of melasma.
Methods
This randomized split‐face controlled study enrolled 20 female patients with bilateral melasma. In each patient, one side of the face received monthly intradermal rhCol III (4 mg/mL) injection, while the contralateral side received intradermal TXA (50 mg/mL) injection, for a total of five treatment sessions. Treatment efficacy was assessed at baseline and 1 month after the final treatment using the VISIA skin imaging analysis system and dermoscopy. The Hemi‐modified Melasma Area and Severity Index (Hemi‐mMASI) was continuously evaluated through the 4‐month posttreatment follow‐up. Patient satisfaction and pain intensity, assessed using the visual analog scale (VAS), were also recorded.
Results
Both intradermal rhCol III and TXA injections significantly improved Hemi‐mMASI scores ( p < 0.001), with no significant difference in the degree of melasma improvement between the two treatments. Pain intensity was significantly higher during TXA injection than during rhCol III injection ( p < 0.001).
Conclusions
Intradermal rhCol III and TXA injections were both effective and well tolerated for melasma. Both treatments may serve as promising adjunctive options in combination treatment strategies for melasma. Compared with TXA, rhCol III showed comparable efficacy in improving melasma severity and was associated with less injection‐related pain.
Zitieren
APA
Li, W., Li, J., Fan, H., Cui, F., & Rang, Z. (2026). Intradermal Recombinant Humanized Collagen Type III for Melasma: Split‐Face Randomized Comparison With Tranexamic Acid. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/2727867
Vancouver
Li W, Li J, Fan H, Cui F, Rang Z. Intradermal Recombinant Humanized Collagen Type III for Melasma: Split‐Face Randomized Comparison With Tranexamic Acid. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/2727867
BibTeX
@article{Li2026,
author = {Li, Wenjie and Li, Juan and Fan, Huiyun and Cui, Fan and Rang, Zhen},
title = {Intradermal Recombinant Humanized Collagen Type III for Melasma: Split‐Face Randomized Comparison With Tranexamic Acid},
journal = {Dermatologic Therapy},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/dth/2727867}
}
EUVIMED